Feature | September 15, 2010| Dave Fornell

New Antiplatelet Drug May Offer Benefits Over Clopidogrel

A new class of antiplatelet therapy drug pending U.S. Food and Drug Administration (FDA) clearance may offer greater benefits over clopidogrel (Plavix) the current standard of therapy. The new drug also offers the ability to have its effects reversed quickly. In late July, the FDA Cardiovascular and Renal Drugs Advisory Committee voted 7-1 recommending final approval of ticagrelor (Brilinta) for the reduction of thrombotic events in patients with acute coronary syndromes (ACS). While the FDA is not required to follow the approval recommendation from the committee, the agency takes the advice into consideration when rendering its final decisions. The FDA was expected to make a final decision by September, but recently granted an extension until December 16 for further review. According to the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study of more than 18,000 patients, ticagrelor was superior to clopidogrel in the long-term reduction of cardiovascular events. Data showed ticagrelor reduced cardiovascular death, heart attacks and stroke over clopidogrel (9.8 vs. 11.7 percent), without an increase in overall major bleeding (11.6 vs. 11.2 percent). Unlike clopidogrel or prasugrel (Effient), approved a year ago, ticagrelor is the first reversible oral antiplatelet drug. This may offer benefits for patients who need to undergo surgery or suffer trauma. Current protocols usually call for patients to stop taking clopidogrel several days prior to surgery to prevent major bleeding complications. Meaningful Use Finally Defined The 2009 Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), part of the federal stimulus package, was supposed to inject more than $20 billion into healthcare information technology (IT). However, a year, later very little of that money has been spent because the government stipulated that funds should only be used for technology meeting the nebulous definition of “meaningful use.” In July, final meaningful use regulations were announced by the Centers for Medicare and Medicaid (CMS) and the Office of the National Coordinator for Health Information Technology (ONC). These rules define the incentive payments program attached to healthcare technology. The rules also outlined standards and certification requirements for electronic medical record (EMR) systems. The goal of HITECH is to achieve widespread adoption of EMRs by 2014. CMS will administer an incentive payments program that will make significant bonus payments available to eligible healthcare providers who adopt and demonstrate meaningful use of certified EMRs. For details and a complete listing of the new regulations, visit the U.S. Department of Health and Human Services health IT site at: http://healthit.hhs.gov/portal/server.pt?open=512&objID=2996&mode=2. Sorry about the long link, but it is the federal government after all. Included in this issue of Diagnostic and Interventional Cardiology is a comparison chart for cardiovascular information systems (CVIS) and cardiovascular picture archiving and communications systems (PACS), starting on page 5. There has been a big question among healthcare IT vendors as to how meaningful use would effect their products. However, all the large healthcare vendors have given commitments to their customers that they will provide whatever is needed to meet any new federal requirements – as if they have a choice in the matter if they want to stay in business. Hybrid Planning Needs Clinical Engineers The July/August issue of DAIC included a story about what is needed when planning a hybrid cath lab/operating room. Frank E. Nickells Jr., CBET, clinical engineering support manager, CHI/Centura Health Supply Chain Management, responded to the story and said clinical engineers were missing on a list of key players to include on a planning committee. He wrote, “All key persons listed are necessary, but clinical engineering is at least as important as facilities engineering. Facilities engineering is important for planning this venture, but clinical engineers will live with and support this product for the next seven to 10 years through either direct support or contract support.” Nickells said facility engineers do not affect down-time and revenue generation during the hybrid’s operational life, whereas clinical engineers do. He said they also should be involved in the purchasing phase of the project. The Web link to last month’s story on how to plan for a hybrid lab installation can be found at www.dicardiology.net/node/37175.

Related Content

PICOM, Scimage, Cardiac PACS, CVIS

ScImage's PICOM system is an example of a CVIS that unifies the IT needs of several cardiovascular service lines into a single cardiology department reporting and image management system. This includes cardiac imaging, echo, ECG management and cath lab reporting. 

Feature | Cardiac PACS| October 08, 2015 | Dave Fornell
Cardiovascular information systems (CVIS or cardiac PACS) have undergone a transformation over the past few years to
CMS, Stage 3 Meaningful Use final rule, ONC, healthcare IT, electronic health records, EHR
Feature | Information Technology| October 07, 2015
The Centers for Medicare and Medicaid Services (CMS) released the final version of Stage 3 Meaningful Use (MU)...
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
ONC, Federal Health IT Strategic Plan 2015-2020, information technology, healthcare
Feature | Information Technology| September 22, 2015
The U.S. Department of Health and Human Services’ Office of the National Coordinator for Health Information Technology...
Frost & Sullivan, top medical technologies, growth, healthcare

Corindus CorPath Vascular Robotic System image courtesy of Corindus Vascular Robotics.

Feature | Information Technology| September 22, 2015
Frost & Sullivan released its list of top medical technologies for 2015, featuring an array of sophisticated...

Big data from regional health exchanges can help identify patients who are at high risk for developing cardiovascular disease and stroke based on blood pressure readings and trends from their office visits over time that arestored in the electronic health records. This information can be used to target these patients with more followups, education and more intensive prevention programs. 

Feature | Information Technology| September 22, 2015 | Jeff Zagoudis and Dave Fornell
As healthcare converts to an entirely electronic health record (EHR)-based system, it opens up new opportunities to m
Brilinta, expanded indication, long-term use, FDA

Brilinta image courtesy of AstraZeneca

Technology | Antiplatelet and Anticoagulation Therapies| September 15, 2015
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a...
New Haven Pharmaceuticals, FDA approval, Durlaza, antiplatelet, once-daily, extended-release
Technology | Antiplatelet and Anticoagulation Therapies| September 11, 2015
New Haven Pharmaceuticals Inc. announced U.S. Food and Drug Administration (FDA) approval of Durlaza (aspirin) 24-hour...
McKesson Cardiology, CVIS, cardiovascular information system, cardiac PACS
Feature | Cardiac PACS| September 11, 2015 | Shawn McKenzie, MPA, president, CEO, and Val Kapitula, Ascendian Healthcare Consulting
The cardiovascular service line, whether existing within the confines of an acute-care environment or outpatient sett
Overlay Init